BIOMARIN PHARMACEUTICAL INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.07 USD | +0.79% |
|
-0.60% | -22.14% |
Financials (USD)
| Sales 2024 * | 2.74B | Sales 2025 * | 3.09B | Capitalization | 14.25B |
|---|---|---|---|---|---|
| Net income 2024 * | 364M | Net income 2025 * | 509M | EV / Sales 2024 * | 4.95 x |
| Net cash position 2024 * | 698M | Net cash position 2025 * | 1.34B | EV / Sales 2025 * | 4.19 x |
| P/E ratio 2024 * |
40.8
x | P/E ratio 2025 * |
28.7
x | Employees | 3,401 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.13% |
More Fundamentals
* Assessed data
More news
Latest transcript on BioMarin Pharmaceutical Inc.
More recommendations
More press releases
More news
| 1 day | +0.79% | ||
| 1 week | -0.60% | ||
| 1 month | -7.05% | ||
| 3 months | -12.99% | ||
| 6 months | -17.58% | ||
| Current year | -22.14% |
1 week
73.68
75.78
1 month
73.6885.04
Current year
73.6899.25
1 year
73.6899.56
3 years
70.73117.77
5 years
62.88131.95
10 years
55.36151.75
| Managers | Title | Age | Since |
|---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | Nov. 30 |
Brian Mueller
DFI | Director of Finance/CFO | 50 | 02-11-30 |
C. Guyer
CTO | Chief Tech/Sci/R&D Officer | 62 | 20-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Pyott
BRD | Director/Board Member | 70 | 16-01-03 |
Randy Meier
CHM | Chairman | 65 | 06-12-13 |
Elaine Heron
BRD | Director/Board Member | 76 | 02-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.45% | 1 M€ | -.--% | - | |
| 1.79% | 0 M€ | 0.00% | - | |
| 1.59% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 75.07 | +0.79% | 2,545,839 |
| 24-05-30 | 74.48 | -0.77% | 2,073,969 |
| 24-05-29 | 75.06 | +0.85% | 2,759,985 |
| 24-05-28 | 74.43 | -1.44% | 2,864,080 |
| 24-05-24 | 75.52 | -0.50% | 2,028,948 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.
Sector
Pharmaceuticals
Calendar
2024-07-29
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
75.07
USD
Average target price
109.3
USD
Spread / Average Target
+45.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -22.14% | 14.25B | |
| -2.29% | 89.87B | |
| -3.95% | 37.57B | |
| -13.07% | 32.75B | |
| +63.05% | 26.47B | |
| -7.96% | 12.99B | |
| -9.33% | 11.93B | |
| -46.33% | 10.84B | |
| +5.77% | 9.11B | |
| -17.66% | 7.32B |
- Stock Market
- Equities
- BMRN Stock
